Kan Ve Kan Ürünleri Transfüzyonu Yapılan Ve Yapılmayan Hematolojik Maligniteli Hastalarda Hepatit B Ve Hepatit C Virüs Seropozitifliği
Yükleniyor...
Dosyalar
Tarih
2000
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Turgut Özal Tıp Merkezi Dergisi
Erişim Hakkı
Attribution 3.0 United States
info:eu-repo/semantics/openAccess
info:eu-repo/semantics/openAccess
Özet
Kan ve kan ürünleri transfüzyonu öyküsü olan ve olmayan hematolojik maligniteli hastalarda, hepatitB ve hepatit C virüs seropozitifliği arasındaki fark araştınldı. Materyal ve metot: Hematoloji servisinde tedavi edilen, kan transfüzyon öyküsü olan 35 ve transfüzyon öyküsü olmayan 52 hematolojik maligniteli hastada HBs Ag, anti-HBs ve anti-HCV antikor pozitifliği EUSA yöntemi He araştınldı. Bulgular: Çalışmamızda hematolojik malign hastalığı olup transfüzyon yapılmış ve transfüzyon öyküsü olmayan gruplarda birer hastada anti-HCV seropozitifliği saptandı (%2.8, %1.9). HBs Ag seropozitifliği transfüzyon yapılan hasta grubunda %22.8 (n=8), transfüzyon yapılmayan hasta grubunda %5.7 (n=3), kontrol grubunda ise %9 (n=9) olarak bulunmuştur. Anti-HBs antikor seropozitifliği transfüzyon yapılan hasta grubunda %31.4 (n=ll), transfüzyon yapılmayan hasta grubunda %38.4 (n=20), kontrol grubunda %40 (n=43) oranında saptanmıştır. Sonuç: Kan transfüzyonu yapılmış olan hematolojik maligniteli hastalarda HBs Ag seropozitifliği, kan transfüzyonu yapılmamış hasta ve kontrol grubundan daha yüksek bulundu (p<0.05).
We investigated the seropositivity difference of hepatitis B and hepatitis C viruses in hematologically malignant patients with history of blood and blood products transfusions. Material and methods: HBs Ag, Anti-HBs and anti-HCV antibody positivity were investigated in 35 hematologically malignant patients with history of transfusions and 52 patients without history of transfusions with ELISA in the department of Hematology. Results: Anti-HCV positivity was detected in 2.8% (n= 1) and 1.9% of patients (n= 1) with and without blood transfusion history, respectively. HBs Ag positivity was detected to be 22.8% (n= 8) in blood transfused group, and 5.7% (n= 3) in non-transfused group and 9% (n= 9) in the control group. Anti-HBs antibody positivity was detected in 31.4% of patients (n= 11) with a history of blood transfusion, 38.4% in the non-transfused group (n= 20), and 40% in the control group (n= 43). Conclusions: HBs Ag positivity was found to be significantly higher in the transfused group when compared with the non-transfused group and the control group (p<0.05).
We investigated the seropositivity difference of hepatitis B and hepatitis C viruses in hematologically malignant patients with history of blood and blood products transfusions. Material and methods: HBs Ag, Anti-HBs and anti-HCV antibody positivity were investigated in 35 hematologically malignant patients with history of transfusions and 52 patients without history of transfusions with ELISA in the department of Hematology. Results: Anti-HCV positivity was detected in 2.8% (n= 1) and 1.9% of patients (n= 1) with and without blood transfusion history, respectively. HBs Ag positivity was detected to be 22.8% (n= 8) in blood transfused group, and 5.7% (n= 3) in non-transfused group and 9% (n= 9) in the control group. Anti-HBs antibody positivity was detected in 31.4% of patients (n= 11) with a history of blood transfusion, 38.4% in the non-transfused group (n= 20), and 40% in the control group (n= 43). Conclusions: HBs Ag positivity was found to be significantly higher in the transfused group when compared with the non-transfused group and the control group (p<0.05).
Açıklama
Turgut Özal Tıp Merkezi Dergisi.7 (1) :109-112,2000. Malatya.
Anahtar Kelimeler
Hepatit, transfüzyon, hematolojik malignite
Kaynak
İnönü Üniversitesi Turgut Özal Tıp Merkezi Dergisi
WoS Q Değeri
Scopus Q Değeri
Cilt
7
Sayı
2
Künye
Sarı, R.; Özkan, Halil İ.;Sevinç, A.;Aydogdu, İ.;Turgut Özal Tıp Merkezi Dergisi.7 (1) :109-112,2000. Malatya.
